C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 5/10 (2006.01) A61K 35/14 (2006.01) A61K 38/17 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) C12N 15/85 (2006.01) C12N 15/24 (2006.01)
Patent
CA 2590401
The invention provides for compositions, e.g., pharmaceutical compositions, comprising a T lymphocyte, or a population thereof, expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response. The invention further provides an isolated T lymphocyte, or population thereof, expressing at least one recombinant polynucleotide encoding the cytokine, wherein the polynucleotide comprises a non-native coding sequence encoding the cytokine. Also provided is the use of such compositions and T lymphocytes, or populations thereof, for the treatment or prevention of a medical condition e.g., cancer. A method of preparing the a T lymphocyte with enhanced T cell survival is further provided herein.
La présente invention a trait à des compositions, par exemple, des compositions pharmaceutiques, comportant un lymphocyte T, ou une population de ceux-ci exprimant au moins un polynucléotide recombinant codant pour une cytokine qui améliore la survie de lymphocytes T lors de la phase de contraction d'une réponse immunitaire. L'invention a également trait à un lymphocyte T isolé, ou une population de ceux-ci, exprimant au moins un polynucléotide recombinant codant pour la cytokine, ledit polynucléotide recombinant comportant une séquence codante non native codant pour la cytokine. L'invention a trait en outre à l'utilisation de telles compositions et de lymphocytes T, ou des populations de ceux-ci, pour le traitement ou la prévention d'une condition médicale, par exemple, le cancer. L'invention a trait enfin à un procédé de préparation d'un lymphocyte T avec une survie de lymphocyte T améliorée.
Hsu Cary
Morgan Richard A.
Rosenberg Steven A.
Department Of Health And Human Services Government Of The United States Of America Represented By The Se
Ridout & Maybee Llp
LandOfFree
Adoptive immunotherapy with enhanced t lymphocyte survival does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adoptive immunotherapy with enhanced t lymphocyte survival, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adoptive immunotherapy with enhanced t lymphocyte survival will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2015263